Biotech Analyst Devarakonda discusses unmet need in rare lung disease, herapeutic landscape and the challenges with current therapies and the pipeline of drugs under development (relevant companies BMY, UTHR, RHHBY, AMGN, PLRX, FGEN) on an Analyst/Industry conference call to be held on July 16 at 11 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers price target lowered to $41 from $43 at Barclays
- VYNE Therapeutics announces appointment of Banerjee as SVP
- Ex-Dividend Date Nearing for These 10 Stocks – Week of July 1, 2024
- 2seventy Bio announces sale of Hemophilia A candidate for up to $40M
- Bristol Myers Squibb call volume above normal and directionally bullish